Madyoon H, Croushore L
Interventional Cardiology Laboratory, St. Joseph's Medical Center, Stockton, California, USA.
J Interv Cardiol. 2001 Apr;14(2):179-85. doi: 10.1111/j.1540-8183.2001.tb00731.x.
Many of the longstanding challenges in interventional cardiology, such as restenosis and thrombosis, have been met. However, radiocontrast-induced nephropathy (RCN) continues to be problematic, particularly as the population of patients who are diagnosed and treated for vascular occlusions in the cardiac catheterization laboratory have become increasingly older and more complex. Introduction of nonionic contrast media has not eliminated this problem. We present the cases of four high risk patients whom we treated with a newly available renal vasodilator, fenoldopam, as a strategy to prevent RCN and its associated morbidity and mortality.
介入心脏病学中许多长期存在的挑战，如再狭窄和血栓形成，已经得到解决。然而，放射造影剂诱导的肾病（RCN）仍然是个问题，特别是随着在心脏导管实验室诊断和治疗血管闭塞的患者群体越来越老龄化且病情越来越复杂。非离子型造影剂的引入并未消除这一问题。我们介绍了四位高危患者的病例，我们使用一种新上市的肾血管扩张剂非诺多泮对他们进行治疗，作为预防RCN及其相关发病率和死亡率的一种策略。
